Advagen Inc.
This article was originally published in Start Up
Executive Summary
A re-start of DirectGene Inc., Advagen Inc. will marry its gene therapy for prostate cancer to newly in-licensed IP covering small peptide ligands with an affinity for the PSMA receptor. The company believes its new platform will greatly enhance adenovirus targeting and facilitate systemic delivery of gene therapies for a variety of cancers.
You may also be interested in...
CombinatoRx Inc.
CombinatoRx's platform screens combinations of known drugs to find pairs that could deliver a one-two punch to diseases such as cancer and rheumatoid arthritis.
NutraGenomics Inc.
NutraGenomics Inc. is using a systems approach to identify diet-responsive genes and SNPs involved in chronic diseases such as Type 2 diabetes, obesity, atherosclerosis, and certain cancers, using proprietary mouse models to examine dietary effects on genes, proteins, transcription, and metabolism.
Nutrigenomics Start-Ups
Paths to commercialization are uncertain in nutrigenomics, an emerging science which seeks to identify gene-food interactions that differ among subpopulations and between individuals and to personalize diets to prevent disease.